Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

18.2%

2 terminated/withdrawn out of 11 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

114%

8 of 7 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 3

3(33.3%)

Phase 2

2(22.2%)

Phase 4

2(22.2%)

Phase 1

2(22.2%)

9Total

Phase 3(3)

Phase 2(2)

Phase 4(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT04957485Phase 2Active Not Recruiting

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

Role: lead

NCT05534984Phase 3Terminated

Study of Tecovirimat for Human Mpox Virus

Role: collaborator

NCT05380752Unknown

Tecovirimat Intravenous Treatment for Orthopox Virus Exposure

Role: collaborator

NCT04485039Phase 4Completed

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Role: lead

NCT04971109Phase 3Completed

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

Role: lead

NCT04392739Phase 4Completed

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

Role: lead

NCT03972111Withdrawn

A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox

Role: lead

NCT02474589Phase 3Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

Role: lead

NCT00431951Phase 1Completed

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers

Role: lead

NCT00728689Phase 1Completed

Phase I Trial of an Investigational Small Pox Medication

Role: lead

NCT00907803Phase 2Completed

Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

Role: lead

All 11 trials loaded